As the rationale for using PC‐mAb to treat adverse cardiac remodelling following unreperfused MI was to inhibit the pro‐inflammatory response, TLR4, as a triggering factor of the inflammatory response,8 and phosphorylcholine co‐localization was investigated. Here, TLR4 is linked to myocardial infarction.